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Abstract: Two multi-system disorders, Myotonic Dystrophies type 1 and type 2 (DM1 and DM2), are complex neuro-
muscular diseases caused by an accumulation of expanded, non-coding RNAs, containing repetitive CUG and CCUG 
elements. Similarities of these mutations suggest similar mechanisms for both diseases. The expanded CUGn and CCUGn 
RNAs mainly target two RNA binding proteins, MBNL1 and CUGBP1, elevating levels of CUGBP1 and reducing levels 
of MBNL1. These alterations change processing of RNAs that are regulated by these proteins. Whereas overall toxicity of 
CUGn/CCUGn RNAs on RNA homeostasis in DM cells has been proven, the mechanisms which make these RNAs toxic 
remain illusive. A current view is that the toxicity of RNA CUGn and CCUGn is associated exclusively with global mis-
splicing in DM patients. However, a growing number of new findings show that the expansion of CUGn and CCUGn 
RNAs mis-regulates several additional pathways in nuclei and cytoplasm of cells from patients with DM1 and DM2. The 
purpose of this review is to discuss the similarities and differences in the clinical presentation and molecular genetics of 
both diseases. We will also discuss the complexity of the molecular abnormalities in DM1 and DM2 caused by CUG and 
CCUG repeats and will summarize the outcomes of the toxicity of CUG and CCUG repeats.  
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INTRODUCTION 
  Myotonic dystrophies (DMs) are autosomal dominant, 
multisystem diseases with a common pattern of clinical signs 
and symptoms such as myotonia, muscular dystrophy, car-
diac conduction defects, cataracts, and endocrine disorders. 
In 1909, the German Steinert and the British doctors Batten 
and Gibb described the “classic” type of myotonic dystrophy 
(DM1, OMIM 160900) [1,2]. Later in 1912, uncovering high 
frequencies of familial cataracts in DM1 led to the recogni-
tion of DM1 as “multisystem disorder” [3,4]. DM1 is charac-
terized by genetic anticipation. This term was introduced in 
1918 to define lowering of the age of onset and aggravation 
of the disease in consecutive generations [5]. In 1994, a dif-
ferent multisystem disorder was identified with comparable 
clinical features to DM1 but with missing the DM1 CTG 
repeat expansion [6,7]. In Europe, the disease has been 
termed “Proximal Myotonic Myopathy” (PROMM, OMIM 
160900), and in the United States “myotonic dystrophy with 
no CTG repeat expansion”. After a genetic discovery of the 
PROMM mutation in 2001 [8], and re-classification [9], the 
myotonic dystrophies are now termed DM1 for the classic 
type, and DM2 for all other late-onset proximal myotonia 
with the DM2 mutation. Both types of DM belong to the 
group of most variable human disorders distressing almost 
all systems of the human body.  
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CLINICAL PRESENTATION OF DM1 AND DM2 
DM1: Congenital form of Disease 
  Congenital Myotonic Dystrophy (CDM) exists only in 
DM1. In 1960, Dr. Vanier has described 6 children with 
DM1 (the youngest one was 9 months old) with the disease 
manifestation at the time of birth [10]. After this first mile-
stone description, additional case reports and larger series 
gave a more comprehensive description of the CDM pheno-
typic variation [reviewed in 4]. CDM onset varies from the 
pre-/postnatal period to adulthood. Within a wide clinical 
spectrum of CDM, there are some separate phenotypes ac-
cording to the age of onset and the number of copies of CTG 
repeats. Genotype phenotype correlations in CDM showed 
an insignificant raise of CTG repeats in the juvenile-adult 
form of disease with the longer expansions in patients with 
childhood onset [4]. The largest CTG repeat expansions (> 
1,500) are observed in patients with CDM [4].  
  Because of the large expansions of CTG repeats, CDM 
children may be born as premature infants. In many reported 
pregnancies, fetal movements are reduced and polyhydram-
nios occurred. Postnatal hypotonia and immobility are im-
portant first symptoms of CDM. In up to 50% of CDM, bi-
lateral talipes and other contractures are present at birth. Fa-
cial diplegia with a tent-formed upper lip and a high arched 
palate is a characteristic feature. This weakness causes a 
weak cry and the inability to suck in approximately 75% of 
affected newborns. In survivors hypotonia is steadily im-
proving and only rarely prominent at 3–4 years of age, but 
facial diplegia leads to the typical facial “carp-mouth” ap-
pearance. Respiratory complications are frequent in neo-78    Current Genomics, 2010, Vol. 11, No. 2  Schoser and Timchenko 
nates. Severely affected neonates requiring ventilation for 
more than 4 weeks will die from respiratory problems. De-
layed motor development is an important feature at post-
natal stages. Almost all children become able to walk inde-
pendently. Mental retardation is observed to a variable de-
gree in a great number of affected individuals but normal 
mental development is possible, even if motor development 
is delayed. Rarely, attention deficit hyperactivity and anxiety 
disorders, autism, behavioural problems, and depression are 
reported in childhood. Despite the severe muscular pheno-
type, clinical myotonia is neither a feature presented in the 
neonatal period nor can it be disclosed in the electromy-
ogram (EMG). Furthermore there is a high frequency for 
other associated abnormalities such as inguinal or hiatus her-
nia, undescended testis, congenital dislocation of the hip and 
heart defect, hydrocephalus, congenital cataract, and cleft lip 
[4, 11]. 
Phenotype of Adult DM1  
  The adult onset clinical phenotype is the most typical 
appearance of DMs. The core features are facial weakness 
with ptosis and distal muscle weakness. Grip and percussion 
myotonia are regular features; however, myotonia affects 
any other muscle including bulbar, tongue or facial muscles, 
causing problems with talking, chewing, and swallowing. 
Furthermore, a 3- to 7-fold elevation of the serum creatine 
kinase is apparent. Cardiac involvement includes conduction 
abnormalities with arrhythmia and conduction blocks up to 
sudden cardiac death. In some patients and families, a dilated 
cardiomyopathy may be observed. Central nervous system 
involvement covers cognitive impairment/mental retardation, 
specific patterns of psychological dysfunction, personality 
traits, neuropsychological changes, and excessive daytime 
sleepiness. Some of these features may be related to altera-
tions found by neuroimaging and neuropathology (e.g. tau 
protein abnormalities). The most common eye defect are the 
posterior capsular cataracts and, rarely, pigmentary retinal 
degeneration. Gastrointestinal tract involvement covers irri-
table bowel syndrome and symptomatic gall stones and, 
gamma-glutamyltransferase elevations. Finally, endocrine 
abnormalities include testicular atrophy, hypotestosteronism, 
insulin resistance with usually mild type-2 diabetes (Fig. 1-
3) [4, 11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Common clinical presentation in DM1 and in DM2. (A) 
Grip myotonia in a DM2 patient. Reduced speed of first opening 
and weakness of the finger flexors. (B) Electromyographic record-
ing of the tibialis anterior muscle from a DM1 patient with a classic 
myotonic discharge. Note the decrescendo character of the sponta-
neous motor unit activity. (C) Representative posterior iridescent 
cataract in a DM2 patient. 
DM1 Aging, Prognosis, and Outcome 
  By aging, more proximal and axial muscle weakness is 
common and many patients are wheelchair bound. Neverthe-
less, myotonia decreases by progressive muscle atrophy. 
Late, but prominent respiratory insufficiency occurs by dia-
phragmatic weakness. Still, cognitive impairment increases. 
The majority of DM1 patients have overt type-2 diabetes at 
older ages. Thus, in summary, many patients become se-
verely disabled by their fifth and sixth decades of life. Chest 
infections, partly by aspiration, and diaphragm weakness are 
common and may precipitate respiratory failure. Sudden 
cardiac death is not uncommon, even in younger patients, 
and may be preventable, at least in part, by cardiac pace-
maker implantation. On the other side, especially in late-
onset or asymptomatic patients (with low number of CTG 
repeats), only limited features are found on clinical and para-
clinical assessment. In late-onset patients, the search for 
cataracts is helpful for identifying the transmitting person 
[4,11]. 
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Fig. (3). Differences in clinical presentation of adult DM1 and 
DM2. A classic forearm atrophy is shown for patient with DM1 (A) 
but not with DM2 (B). The “core” characteristic of DM2 is a typical 
predominant lower leg weakness and atrophy (B).  
Clinical Phenotype of DM2 
  The most important discrepancy between DM1 and DM2 
is absence of a congenital or early-onset form in DM2 [9, 
11,12]. Exercise-induced fatigue and myalgia and/or mild 
grip myotonia and myotonia of the proximal legs, e.g. while 
climbing a staircase, and sometimes early neck flexor weak-
ness are the most frequent early symptoms in patients af-
fected with DM2. A core pattern of DM2 phenotype is 
proximal leg weakness and stiffness, deep finger and neck 
flexor weakness that appear between the fourth and sixth 
decades of patients’ lifespan. Patients have difficulties rising 
from squat, climbing stairs or rising from a chair. Muscle 
atrophy is only mild and almost never seen in the forearm. In 
some patients, muscle hypertrophy of the calves may be no-
ticed. Highly patchy and temporary, abundant myalgia is 
regular. Mild to moderate, but even very high elevation of 
the serum creatine kinase may be found. Cardiac involve-
ment with mild arrhythmia and conduction blocks up to sud-
den cardiac death can be noticed [11,13]. Progressive dilated 
cardiomyopathy seems to be more common in DM2 than in 
DM1. Central nervous system involvement covers mild cog-
nitive dysfunctions, some psychological dysfunction, ab-
normal personality traits, neuropsychological changes and 
daytime sleepiness. Like in DM1, these findings may be as-
sociated with the reported alterations found by neuroimaging 
and may be connected to tau protein abnormalities [14]. 
Most common feature of DM2 phenotype is posterior capsu-
lar cataracts. Gastrointestinal tract involvement is limited, 
but elevations of gamma-glutamyltransferase levels are fre-
quently noticed [11,15]. Endocrine abnormalities consist of 
insulin resistance with mild type-2 diabetes, hypothyroidism, 
hypotestosteronism, and rarely testicular hypotrophy (Fig. 1-
3).
 
DM2 Aging, Prognosis and Outcome 
  By aging, more axial and distal muscle weakness is 
common and some patients are wheelchair bound. Myotonia 
decreases by progressive muscle atrophy. Even late, there is 
seems no overt respiratory insufficiency. Cognitive impair-
ment increases very slowly. Only some of DM2 patients 
have overt diabetes at older age. Thus, in summary, only few 
patients become severely disabled by the sixth to eighth dec-
ades. However, there are seems to be many asymptomatic 
and undiscovered DM2 patients. Even by careful clinical and 
paraclinical assessment, sometimes it is challenging to rec-
ognize DM2 phenotype [11,15]. Thus, future collection of 
clinical data will show how DM2 mutation affects aging.  
How to Make the Correct Clinical Diagnosis in both 
DM? 
DM1 
  The obvious clinical phenotype and the family history 
helps the diagnosis. In late-onset patients, different special-
ists may be involved in the treatment of symptoms. Genetic 
analysis is used to identify and/or confirm the diagnosis. 
Therefore, muscle biopsy is only rarely required. However, 
muscle biopsies are required in cases with neuromuscular 
complaints and with negative genetic analysis [11,16].  
DM2 
  Different specialists may initially be involved in diagnos- 
tics. When proximal weakness or myotonia becomes obvi- 
ous, together with a positive family history, diagnosis can be  
made. Genetic analysis is advised to confirm the diagnosis.  
A muscle biopsy may be required in asymptomatic neuro- 
muscular patients or when genetic analysis for DM1 and   
DM2 is negative. 
 
MOLECULAR GENETICS IN DM 
  In 1992, DM1 mutation has been discovered on chromo-
some 19q as an expansion of CTG repeats in the 3’ untrans-
lated region of the dystrophia myotonica-protein kinase 
(DMPK) gene [4,15,17,18]. The incidence of DM1 is 13: 
100,000, the prevalence 2-5 / 100,000, in the congenital form 
1: 3,500 [4,11,15]. The length of CTG expansions varies 
from 80 to more than 4,000 repeats in affected patients, and 
the length of expansion is from 50 to 100 CTG repeats in 
asymptomatic patients. Somatic instability has been reported 
in different tissues over lifespan with repeat size elongation 
of ~50-80 repeats per year. Intergenerational instability is 
frequent, with expansions of several thousand repeats occur-
ring in a single generation, most commonly secondary to 
maternal transmission [4,11,15].
 There is a relative correla-
tion between the length of CTG repeat expansions and age of 
onset for DM1 patients with CTGs <400, but correlation 
between repeat length and disease severity is poor for long 
repeats [4,11,15] (Table 1). 
  In 1998, the DM2 locus was mapped to 3q21 and, there-
after, the mutation was identified as a CCTG expansion in 
intron 1 of the zinc finger protein 9 (ZNF9) gene [19, 20]. 
On the expanded alleles, an uninterrupted variant of the 
CCTG portion of the repeat tract is elongated [19] (Table 1). 
Expanded DM2 alleles show extraordinary somatic instabil-
ity with significant increases in length over time (e.g. 2000 
bp/3 years) and expanded alleles often appear as smears by 
Southern blotting analysis [8,21]. The incidence and preva-
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Haplotype analyses of DM2 families suggested that the DM2 
expansions may have originated from one or more founder 
mutations and showed evidence that the normal repeat tract 
found in humans has a conserved biological function [21,22]. 
The age of the founding haplotype and the DM2 (CCTG) 
expansion mutation is estimated at approximately 200 to 540 
generations [21]. A family of apparently Afghan ancestry 
provides some confirmation that the DM2 expansion oc-
curred previous to Aryan migration of Indo-European settled 
Aryana (ancient Afghanistan) in 2000-1000 B.C [21,23]. 
DM1 AND DM2 PATHOLOGIES ARE ASSOCIATED 
WITH TOXICITY OF CUG AND CCUG RNA RE-
PEATS  
The Processing and Fate of the Mutant DMPK mRNA in 
DM1 Cells 
  The experimental work during last 15 years has been 
focused on the molecular mechanisms by which expansions 
of CTG and CCTG repeats cause DM phenotype. Although 
CTG repeats affect expression of DMPK protein and the 
transcription of genes in the DMPK locus (recently reviewed 
in details in [24]), multisystemic nature of DM1 is mainly 
associated with the accumulation of non-coding CUG repeat 
RNA [25-34]. Thus, we will focus this review on the role of 
CUG and CCUG repeats in DM pathology. Numerous ob-
servations present strong evidence that large amounts of 
CUG and CCUG non-coding RNAs are toxic for cell func-
tions. Several hypotheses have been suggested addressing 
mechanisms of the toxicity of expanded non-coding CUG 
and CCUG repeats.  
  Early studies of DM1 mechanisms have investigated the 
transcription and post-transcriptional processing of the mu-
tant DMPK RNA in DM1 patients. The main hypothesis of 
these studies was that the expanded RNA CTG repeats in the 
3’ UTR of DMPK may interfere with transcription, post-
transcriptional modifications (splicing, adenylation and cap 
formation) and export of the mutant DMPK mRNA from 
nucleus to cytoplasm. It has been shown that the mutant 
DMPK mRNA changed processing of wild type DMPK 
mRNA through trans effect presenting the first evidence for 
the toxic role of CUG RNA repeats in DM1 pathology [25]. 
At the same time, the levels of DMPK mRNA varied from 
patient-to-patient [35]. No significant changes in the mutant 
DMPK mRNA stability and polyadenylation have been 
found [36]. Data for the nucleus/cytoplasmic localization of 
mutant DMPK mRNA remain controversial. The pioneering 
study from Dr. Singer’s laboratory showed that the mutant 
DMPK transcripts form large aggregates or foci in nuclei of 
DM1 fibroblasts and in DM1 tissue [26]. However, the for-
mation of nuclear foci did not seem to interfere with the ex-
port of mutant DMPK mRNA from nuclei to cytoplasm [26]. 
Large amounts of the mutant DMPK mRNA have been de-
tected in cytoplasm of DM1 fibroblasts. In contrast to the 
nuclear foci, the cytoplasmic mutant DMPK mRNA was 
detected in small complexes [26]. Other studies demon-
strated that the mutant DMPK transcripts are completely 
blocked in nuclei [37,38]. In addition to the aggregated form 
of mutant DMPK, we have also detected non-aggregated 
forms of the mutant CUG RNA [39]. Other studies also sug-
gested the existence of un-aggregated (soluble) form of the 
mutant DMPK mRNA in DM1 nuclei [40, 41].  
  Several studies have examined common mechanisms of 
aggregation of RNAs. The aggregation of RNAs in nuclei of 
S. cerevisiae has been shown upon block of RNA nuclear 
export [42]. Such retention of the nuclear RNAs in S. cere-
visiae required the components of the nuclear exosome in-
cluding protein RRP6 since deletion of the RRP6 gene re-
leases trapped RNAs from intranuclear foci [43]. One might 
assume that, by analogy to these observations, the aggrega-
tion of the mutant DMPK mRNA in nuclei is likely mediated 
by a reduced processing of the mutant DMPK mRNA. Such 
reduction of the mutant DMPK mRNA export could be be-
cause of diminished capacity of the modification enzymes to 
process the mutant DMPK mRNA. In agreement with this 
hypothesis, it has been shown that a truncated DMPK RNA 
containing long CUG and CAG repeats aggregated in nu-
clear foci; likely due to delay in the processing of transcripts 
with expanded repeats [44]. Two separate studies from Dr. 
Lawrence’ lab and from Dr. Morris’ lab have examined the 
fate of mutant DMPK RNA in DM1 nuclei. They found that 
the mutant DMPK mRNA is located at the periphery of nu-
clear speckles, suggesting that the efficiency of export of the 
mutant DMPK pre-mRNA is reduced [45,46].  
  Despite the nuclear aggregation of the mutant DMPK 
mRNA, a significant portion of this mRNA is still trans-
ported to cytoplasm [26,39,47]. It has been recently found 
that, in DM1 cells, the mutant DMPK mRNA is detected in 
Table 1.  Genetic Etiology of DM1 and DM2 
DM1   DM2  
Chromosomal locus   19q 13.3   3q 21.3  
Gene   DMPK   ZNF9  
Inheritance   autosomal dominant   autosomal dominant  
Mechanism   CTG repeat expansion   CCTG repeat expansion  
Normal repeat size   up to 37   up to 27  
Pathologic repeat size   > 50 CTG   > 75 CCTG?  
Expanded repeat range   50-4000   75-5000->11000 CCTG  
Anticipation   yes   --- Myotonic Dystrophies 1 and 2  Current Genomics, 2010, Vol. 11, No. 2    81 
aggregated forms in both nucleus and in cytoplasm [47]. 
Approximately 23 to 71% of DM1 fibroblasts and myoblasts 
contain CUG foci in both nuclei and in cytoplasm [47]. Iden-
tification of the mutant DMPK in aggregated form in cyto-
plasm of DM1 cells suggests that, like in nuclei, cytoplasmic 
processing of mutant DMPK mRNA might be also reduced 
by the CUG repeat tract. Although cytoplasmic foci do not 
affect splicing activity in DM1 cells, the role of cytoplasmic 
CUG foci in the regulation of translation or stability of 
RNAs has not been studied.  
  One of the possible reasons for the existing controversies 
on the effect of CUG repeats on mutant DMPK nuclear-
cytoplasmic export might be the sensitivity of assays. The 
initial studies showed that the sensitivity of FISH assay is 
very important because cytoplasmic mutant DMPK mRNA 
is detected in the multiple complexes of smaller size rela-
tively to very large nuclear foci [26]. It is important to note 
that recent progress in the detection of microRNAs showed 
that application of locked nucleic acid (LNA), modified oli-
gonucleotides for hybridization with microRNAs, signifi-
cantly increases sensititivity and specificity of hybridization 
[48]. Indeed, application of LNA-CAG probe and inclusion 
of Triton X-100 in the hybridization buffer for detection of 
mutant DMPK mRNA revealed multiple cytoplasmic aggre-
gates of mutant DMPK mRNA in cytoplasm and in nuclei of 
DM1 myoblasts (Dr. Partha Sarkar, personal communica-
tion). Additional studies are required to examine nu-
cleus/cytoplasmic distribution of the mutant DMPK mRNA 
by using different methodological approaches. This issue is 
very important for the development of therapeutic ap-
proaches to treat DM1.  
The Processing and Fate of the Mutant Intron 1 of ZNF9 
in DM2 Cells 
  In DM2, expanded RNA CCUG repeats are located 
within intron 1 of ZNF9 gene [8]. There are two main spliced 
isoforms of ZNF9 [49]. It was expected that the presence of 
CCUG expansion may interfere with splicing of ZNF9 pre-
mRNA. However, two studies failed to detect splicing altera-
tions for ZNF9 in DM2 [50,51]. It has been shown that, in 
DM2 myoblasts, the mutant CCUG RNA is aggregating in 
nuclei similar to the mutant DMPK mRNA in DM1 cells; 
however, these aggregates do not appear to contain se-
quences surrounding CCUG expansion [50]. These findings 
suggest that the pure CCUG repeats are accumulating in 
large aggregates after excision of mutant intron 1 of ZNF9. 
If this is the case, then the accumulation of CCUG repeats in 
large aggregates might lead to the reduction of decay of the 
mutant intron 1 of ZNF9 in DM2 cells.  
  Introns are degraded in nuclei by exosome immediately 
after their excision and linearization. The aggregation of 
CCUG repeats in DM2 nuclei suggests that there is a block 
or delay of the degradation of the mutant intron 1. However, 
investigations of the co-localization of CCUG foci and 
exosome have shown that CCUG repeats are not associated 
with exosome [46]. It is also possible that degradation of the 
mutant CCUG RNA repeats is reduced during excision of 
the mutant intron 1 at the stage of de-branching or lineariza-
tion of intron. Our recent data with ectopic expression of 
RNA CCUG repeats in C2C12 myoblasts showed that short 
RNA CCUG repeats (CCUG36) also aggregate in nuclei and 
in cytoplasm [52]. These data suggest that the large number 
of copies of short RNAs CCUG repeats cannot be normally 
processed resulting in aggregation of CCUG36 RNA. The 
detection of foci containing 36 CCUG repeats in transfected 
C2C12 myoblasts might be also associated with a possible 
increase of their stability. It is likely that some RNA CCUG 
repeats in DM2 myoblasts escape nucleus and migrate to 
cytoplasm [52]. How CCUG repeats might reach the cyto-
plasm? One possibility is that nuclear CCUG repeats could 
migrate to cytoplasm during mitosis when nuclear membrane 
becomes fragile. In addition, there are some examples of 
decay of introns which occurs in cytoplasm [53]. It is impor-
tant to note that cytoplasmic CCUG RNA repeats are found 
not only in proliferating DM2 myoblasts, but also in mature 
tissues such as liver of CCUG transgenic mice [52]. These 
data emphasize that the degradation of the mutant intron 1 of 
ZNF9 should be carefully examined to identify mechanism 
regulating its degradation.  
Toxicity of the Aggregated Forms of CUG and CCUG 
RNAs is Associated with Sequestration of Splicing Regu-
lator, MBNL1 
  The aggregated forms of mutant DMPK mRNA are 
mainly detected in the nuclei of DM1 cells [26,31,32,37,38]. 
The nuclear CUGn aggregates sequester MBNL1 (Muscle-
blind) protein [31,54], causing local reduction of MBNL1. 
Analysis of MBNL1-knock out mice showed that homozy-
gous animals developed main symptoms of DM1: myotonia, 
muscular dystrophy and cataracts [55]. Moreover, adenoviral 
delivery of MBNL1 into CUG-transgenic mice partially cor-
rects myotonia [56]. These data show that sequestration of 
MBNL1 by nuclear CUG aggregates plays an important role 
in DM1 pathology. Since MBNL1 is also sequestered by 
nuclear aggregates containing CCUG repeats in DM2 cells, 
it might play similar role in DM2 pathogenesis. Because 
CCUG expansions are longer than CUG expansions, they 
might sequester large amounts of MBNL1. It remains to ex-
amine the relationship between the reduction of MBNL1 in 
DM2 and relatively mild phenotype of DM2.  
  In the course of studies of molecular pathogeneses of 
DM1 and DM2, it became clear that the mechanisms of these 
diseases are much more complex and are not limited to the 
alterations in splicing. Several recent reports suggest that the 
nuclear aggregates of the mutant DMPK mRNA are not suf-
ficient to cause DM1 phenotype. Although the induction of 
the mutant 3’ UTR of DMPK in mice leads to accumulation 
of nuclear aggregates and to sequestration of MBNL1; these 
mice do not show overt DM1 phenotype [34]. In contrast, 
expression of a high number of copies of the DMPK 3’ UTR 
containing 5 CUG repeats leads to development of DM1-like 
phenotype (myotonia, cardiac conduction defects and mus-
cular dystrophy) in the absence of nuclear CUG foci and in 
the absence of MBNL1 sequestration [34]. What is the 
mechanism by which multiple copies of the normal 3’ UTR 
of DMPK cause DM1 phenotype? Molecular analysis of the 
“inducible” transgenic mice with overt DM1 phenotype 
showed that these mice have increased levels of CUGBP1 
(CUG-binding protein 1) [34]. Based on these results, it is 
reasonable to suggest that DM1 phenotype could be caused 
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of CUGBP1. This suggestion is supported by several other in 
vivo models of DM1. In DM1 Drosophila model (generated 
in the Dr. Botas’ lab), interrupted CUG repeats 
(CUG20CUCGA24) cause muscle wasting and eye degenera-
tion; and this phenotype is rescued by overexpression of 
MBNL1 [57]. The increase of CUGBP1 in muscle of Droso-
phila caused phenotype which is similar to that caused by 
overexpression of CUG repeats [57]. Importantly, flies over-
expressing MBNL1 in the absence of intrerrupted CUG480 
also show muscle phenotype, suggesting that MBNL1 levels 
have to be tightly regulated for normal muscle function. It is 
also interesting that flies with increased CUGBP1 crossed 
with flies expressing interrupted CUG480 RNA showed wors-
ening eye degeneration suggesting that the increase of 
CUGBP1 levels is toxic for normal cells. The co-expression 
of CUGBP1 with interrupted CUG480 increases muscle wast-
ing compared to flies expressing only CUG480 RNA [57].  
  It is important to note that the increase of CUGBP1 
causes degeneration in DM1 Drosophila model without 
binding to the aggregated form (foci) of mutant CUG480 
RNA. This observation suggests that the elevation of 
CUGBP1 and reduction of MBNL1 might cause DM1 phe-
notype through independent mechanisms. One of these pos-
sible mechanisms has been proposed by Dr. Junghans [41]. It 
has been suggested that CUGBP1 and MBNL1 cause DM1 
pathology through the binding to two different forms of mu-
tant CUG RNA: “insoluble” or aggregated CUG repeats 
(MBNL1) and “soluble” or un-aggregated CUG RNA 
(CUGBP1) (Fig. 4). According to this model, the mutant 
RNA with long CUG repeats exists in the double-stranded 
form, stability of which depends on the relative levels of free 
CUGBP1 and MBNL1. MBNL1 binds to the aggregated 
form of CUGn RNA, organized in the double-stranded helix; 
whereas CUGBP1 binds to the melted regions of the CUG 
helix [41]. In this case, saturation of the ds-CUG helix with 
MBNL1 reduces the levels of free MBNL1 facilitating melt-
ing of the ds-CUG helix and promoting CUGBP1 binding to 
the single stranded CUG repeat regions. This model is sup-
ported by electron microscopy data showing that CUGBP1 
protein interacts with the base of the ds-CUG helix [58]. 
However, this model is not consistent with data showing that 
the elevation of CUGBP1 increases the number of CUG ag-
gregates in transgenic flies suggesting that CUGBP1 does 
not melt, but rather stabilizes CUG aggregates [57]. Thus, 
the understanding of the relationships between CUGBP1 and 
MBNL1 in patients with DM1 requires more experimental 
work. More studies are also needed to determine the contri-
bution of the reduction of MBNL1 and elevation of 
CUGBP1 in DM1 phenotype.  
  While CUG repeats in the Drosophila model, reported in 
[57] were toxic, another DM1 model has shown that the ex-
pression of CUG repeats is not toxic despite accumulation of 
CUG repeats in aggregated form and sequestration of mus-
cleblind [59]. Several strains of transgenic flies expressing 
16, 240 and 480 CUG repeats were generated by Dr. Ait-
Ahmed’s group [60]. Surprisingly, only strain with 240 CUG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). A hypothetical model outlining the role of CUG expansion in the dys-regulation of gene expression at several levels. In the 
nucleus of DM1 patients, double-stranded CUG repeat RNA binds to MBNL1. CUGBP1 binds to the opened ends of the CUG-helix. Trian-
gles show hypothetical positions of other misregulated RNA-binding proteins, which interact with CUG repeats, such as hnRNP H. Un-
aggregated CUG repeats bind to CUGBP1 and TFs affecting splicing of the CUGBP1 targets and reducing transcription. In cytoplasm of 
DM1 cells, the un-aggregated CUG repeats stabilize CUGBP1 increasing levels of CUGBP1 protein. The elevated CUGBP1 alters transla-
tion and stability of mRNAs. CUG repeats also change signal transduction pathways by unknown mechanisms affecting CUGBP1 activity 
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repeats caused overt phenotype assessed by lethality and eye 
degeneration. Transgenic flies expressing 480 CUG RNA 
repeats were asymptomatic despite accumulation of nuclear 
CUG foci and sequestration of muscleblind [60]. This obser-
vation suggests that, in addition to the aggregation of CUG 
repeats and sequestration of muscleblind, other factors are 
involved in CUG RNA toxicity. Since the authors found the 
same levels of expression of RNA CUG repeats in both 
lines, the lack of phenotype in the 480 CUG repeats line 
could not be explained by the differences in the levels of 
CUG-containing transcripts. It is interesting that in the Dro-
sophila line, showing degeneration, insertion occurred in the 
gene encoding zinc finger protein [60]. Thus, sequences sur-
rounding CUG repeat expansion seem to be important for the 
toxicity of CUG repeats.  
  The major toxicity of the mutant CUG and CCUG nu-
clear aggregates is associated with alterations of splicing of 
mRNAs regulated by MBNL1 (Fig. 4, 5) [31]. Analysis of 
splicing of some mRNAs in the DM1 Drosophila  models 
generated by Dr. Artero’s group showed that there is a more 
complicated relationship between global splicing abnormali-
ties and the sequestration of muscleblind. While transgenic 
flies with 480 CUG repeats showed stronger phenotype than 
flies expressing 60 CUG repeats, splicing abnormalities of 
some mRNAs were stronger in the line with lower number of 
CUG repeats [61]. Although the authors concluded that nu-
clear CUG foci may be not toxic (at least in Drosophila), it 
is possible that short CUG repeats (CUG60) cause greater 
abnormalities in splicing of some mRNAs due to higher lev-
els of expression. This suggestion is based on the overt DM1 
phenotype in “tet-inducible” mouse model expressing high 
number of copies of the 3’ UTR of normal DMPK with 5 
CUG repeats [34]. We have recently found that the expres-
sion of short CCUG repeats (CCUG36) in normal myoblasts 
causes changes in RNA processing identical to those ob-
served in DM2 cells. These data support the suggestion that 
the high number of copies of short CCUG repeats have the 
same toxicity as low number of copies of long repeats [52]. 
In addition to aggregated CUG repeats in nuclei, the mutant 
CUG foci are detected in cytoplasm [47]. Whereas cyto-
plasmic CUG foci do not have toxic effect on splicing, they 
likely affect cytoplasmic processes in DM1 cells such as 
translation and RNA stability. 
Toxicity of Soluble CUG and CCUG Repeats is Mediated 
Through the Elevation of CUGBP1 
  One of the molecular hallmarks of DM1 is the elevation 
of CUGBP1 protein and its RNA-binding activity 
[34,39,62,63]. In patients with DM1, CUGBP1 protein is 
increased without significant changes of CUGBP1 tran-
scripts levels [39]. The role of CUG repeats in the elevation 
of CUGBP1 in DM1 has been shown by examination of 
DM1 cellular and mouse models in which expression of 
CUG repeats led to the increase of CUGBP1 [34,39,63-65]. 
However, one DM1 mouse model did not show elevation of 
CUGBP1 [32]. It would be interesting to determine if CUG 
repeats elevate CUGBP1 RNA-binding activity in these 
transgenic mice.  
  The elevation of CUGBP1 has been also reported for 
DM2 patients [52]; however, there are contradictory results 
for expression of CUGBP1 in DM2. Two reports addressing 
total cellular levels of CUGBP1 in DM2 cells did not find 
differences in CUGBP1 levels [66,67]. However, analysis of 
cytopasmic extracts from DM2 cultured myoblasts and from 
muscle biopsies of DM2 patients showed the elevation of 
CUGBP1 [52]. Expression of pure RNA CCUG repeats in 
normal cells also increased levels of CUGBP1 [52]. It has 
been shown that the non-coding CCUG RNA in the DM2 
mouse model generated by Dr. Krahe elevates CUGBP1 
levels [52].  
  The mechanisms by which CUG and CCUG repeats ele-
vate CUGBP1 need additional investigations. Since 
CUGBP1 has been not found in the nuclear CUG and CCUG 
aggregates, nuclear CUG and CCUG foci do not appear to 
affect CUGBP1 levels. On the contrary, identification of 
CUGBP1-RNA complexes from DM1 and DM2 cells by 
biochemical methods shows that CUGBP1 forms stable 
complexes with CUG and CCUG RNAs in DM1 and in 
DM2 correspondingly and these complexes are not detected 
in normal cells [39,52]. The formation of these complexes 
depends on CUG/CCUG RNAs because ectopic expression 
of pure CUG or CCUG RNAs causes interaction of 
CUGBP1 with un-aggregated CUG and CCUG repeats 
[39,52]. In agreement with these observations, the analysis 
of CUGBP1 in tissues from DM2 transgenic mice showed 
that CUGBP1 is associated with cytoplasmic CCUG RNA 
[52]. Immunoprecipitation of CUGBP1 from normal and 
DM1 cultured cells also showed strong interaction of 
CUGBP1 with the mutant DMPK mRNA in DM1 cells but 
not in normal cells [40]. These data suggest that CUGBP1 
interacts in vivo with CUG and CCUG RNAs located outside 
of aggregated CUG and CCUG repeats (Fig. 4,  5). Since 
CUGBP1 mRNA levels are not increased in DM1 cells, it 
was suggested that CUG repeats may increase CUGBP1 sta-
bility. In fact, examination of CUGBP1 half-life in the pres-
ence of CUG repeats showed that CUG repeats stabilize 
CUGBP1 [39]. Recent data revealed that phosphorylation of 
CUGBP1 by PKC kinase also plays a significant role in the 
stabilization of CUGBP1 in DM1 cells [63]. Thus, stabiliza-
tion of CUGBP1 in DM1 is achieved by a complex mecha-
nism involving specific phosphorylation of CUGBP1, its 
interactions with un-aggregated CUG repeats, and possibly 
some other factors.  
  Growing number of new reports suggest that additional 
pathways are involved in the regulation of activity and levels 
of CUGBP1 in DM1 and DM2 cells. Analysis of CUGBP1 
stability in DM2 myoblasts and in normal cells expressing 
CCUG repeats showed that the stability of CUGBP1 is also 
increased in the presence of CCUG repeats [52]. CUGBP1 
phosphorylated isoforms are increased in cytoplasm of DM2 
myoblasts with elevated levels of CUGBP1; thus phosphory-
lation may also play a role in the stabilization of CUGBP1 in 
DM2 cells [52]. In addition, it has been shown that the 20S 
proteasome is inhibited by CCUG repeats in DM2 myoblasts 
increasing stability of proteins [52]. Thus, the increase of 
CUGBP1 stability in DM2 patients may be also due to re-
duced activity of the 20S proteasome.  
Toxic Effect of CUGBP1 Elevation on the Global Splicing 
  Why the increase of CUGBP1 is toxic for cell functions? 
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this protein has many functions and plays an important role 
in several biological processes. CUGBP1 is expressed in 
both nucleus and cytoplasm. Like MBNL1, CUGBP1 has 
splicing activity [62-65,68-70]. CUGBP1 has also several 
important functions in cytoplasm, including regulation of 
protein translation and RNA stability [39,71-84]. Given 
these multiple functions, it is expected that the increase of 
CUGBP1 in DM1 and in some patients with DM2 might 
change splicing, translation and stability of mRNAs, targets 
of CUGBP1. It is interesting that CUGBP1 and MBNL1 
regulate splicing of the same mRNAs (chloride channel 1, 
insulin receptor, troponin T) by binding to different sites 
[24,85]. This suggests that the increase of CUGBP1 or re-
duction of MBNL1 cause similar alterations of splicing in 
DM1 cells. However, transgenic mice overexpressing 
CUGBP1 developed splicing abnormalities suggesting that 
misregulation of splicing of CUGBP1 targets in vivo is inde-
pendent of MBNL1 [68]. It is important to note that, in 
MBNL1 knock out mice, alteration of splicing also occurs 
without CUGBP1 increase [55]. It is likely that MBNL1 and 
CUGBP1 regulate splicing in a tissue specific manner con-
tributing to different symptoms in patients with DM1 and 
DM2.  
Toxic Effect of CUGBP1 Elevation on Translation in 
DM1 and DM2 Cells 
  CUGBP1 regulates cap-dependent and cap-independent 
translation [71-78]. CUGBP1-dependent activation of trans-
lation is mediated by binding of CUGBP1 to mRNAs and to 
translation initiation eIF2 complex and following delivery of 
the mRNAs to polysomes [75]. Interactions of CUGBP1 
with eIF2 require site-specific phosphorylation of CUGBP1 
at Ser302 by cyclin D3-cdk4 kinase [75,76,78]. It has been 
shown that the interaction of CUGBP1 with eIF2 is in-
creased during normal muscle differentiation [78]. It is im-
portant to note that, in DM1 myotubes, this interaction is 
reduced due to low levels of cyclin D3 in cytoplasm of DM1 
cells [78]. As the result, translation of some mRNAs is re-
duced during differentiation of DM1 muscle [72,73,78]. Ec-
topic expression of cyclin D3 promoted the formation of the 
CUGBP1-eIF2 complex in DM1 myotubes and improved 
fusion of DM1 myoblasts [78]. These data show that 
CUGBP1 plays a critical role in the regulation of muscle 
differentiation. Consistent with this suggestion, modulation 
of CUGBP1 levels in animal models dys-regulates normal 
muscle development and differentiation. CUGBP1 trans-
genic mice so far as are the only one mouse model reproduc-
ing symptoms of CDM [73]. CUGBP1 transgenic mice with 
the levels of CUGBP1 matching those in CDM patients (ap-
proximately 5-fold) showed a delay in development and died 
in utero or shortly after birth [73]. Some of the under-
developed pups have survived the postnatal stress only after 
additional supportive measures such as keeping under-
developed pups separately with foster mothers up to 2 
months of age until they are capable to eat dry food.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Hypothetic model for the role of CCUG repeats in DM2 pathology. Like in patients with DM1, CCUG repeats form nuclear 
aggregates presumably containing double-stranded CCUG repeats. This aggregated CCUG RNA sequesters MBNL1 changing splicing of 
mRNAs regulated by MBNL1. It is unknown if CUGBP1 contributes to the alterations in splicing of mRNAs in DM2 cells. In cytoplasm, the 
un-aggregated CCUG repeats bind to two multi-protein complexes containing CUGBP1-eIF2 and the 20S proteasome affecting translation 
and stability of proteins. CCUG repeats also reduce cytoplasmic levels of ZNF9 by unknown mechanism. Since ZNF9 regulates several 
TOP-containing mRNAs, encoding proteins of translational apparatus, the reduction of cytoplasmic ZNF9 causes the reduction of the rate of 
global protein synthesis. Myotonic Dystrophies 1 and 2  Current Genomics, 2010, Vol. 11, No. 2    85 
  In contrast to DM1 myotubes, CUGBP1-eIF2 complexes 
are increased in DM2 differentiating myotubes similar to 
normal myotubes (Timchenko, L.; unpublished; Fig. 6). 
These data suggest that a lack of CDM in patients with DM2 
may be, at least in part, due to normal phosphorylation of 
CUGBP1 at Ser302.  
 
 
 
 
 
Fig. (6). The translational CUGBP1–eIF2 complex is increased 
in control and DM2 myotubes, but not in DM1 myotubes. Cyto-
plasmic extracts from normal, DM1 and DM2 myoblasts (Mb) and 
myotubes (Mt) were incubated with the C/EBP RNA probe and 
separated by native gel electrophoresis (EMSA). The upper frag-
ment of the gel containing the CUGBP1-eIF2 complexes is shown. 
The presence of CUGBP1-eIF2 complex in DM2 myotubes sug-
gests that despite the increase of CUGBP1 in both DM1 and in 
DM2, CUGBP1 translational activity might be normal in DM2 
myotubes.  
Regulation of CUGBP1 RNA-Binding Activity by Phos-
phorylation 
  CUGBP1 has a dual effect on translation of mRNAs 
which depends on the efficiency of the binding of CUGBP1 
to its targets. It has been shown that specificity of interaction 
of CUGBP1 with mRNAs is regulated by phosphorylation 
[75,76,78]. Two specific sites of phosphorylation [targeted 
by Akt (Ser28) and cyclinD3/cdk (Ser302)] were identified 
within CUGBP1 molecule [78]. Examination of CUGBP1 
phosphorylation status in the DMPK knock out mice sug-
gested that CUGBP1 is a possible substrate for DMPK 
kinase [86]. It has been also shown that PKC phopshoryla-
tion regulates CUGBP1 [63]. Although there are several pre-
dicted sites for the phosphorylation of CUGBP1 by PKC, 
additional studies are needed to identify phosphorylation 
sites for PKC and DMPK kinases within the CUGBP1 mole-
cule.  
  It has been shown that the site-specific phosphorylation 
of CUGBP1 by Akt and cyclinD3/cdk4 kinase regulates 
CUGBP1 function during normal myogenesis (Fig. 7). In 
proliferating myoblasts CUGBP1 is phosphorylated by Akt 
and the ph-S28-CUGBP1 has increased binding activity to-
ward mRNA encoding cyclin D1 [78]. As noted above, in 
normal myotubes, CUGBP1 interacts with cyclin D3/cdk4 
complex which phosphorylates CUGBP1 at Ser302 [68]. Ph-
Ser302-CUGBP1 strongly binds to mRNA encoding a cdk 
inhibitor, p21, while binding of CUGBP1 to cyclin D1 
mRNA is weaker. During DM1 myogenesis, phosphoryla-
tion of CUGBP1 and CUGBP1 interactions with its RNA 
targets are altered. In DM1 myoblasts, CUGBP1 is hyper-
phosphorylated by Akt; whereas in DM1 myotubes 
CUGBP1 phosphorylation by cyclinD3/cdk4 is reduced due 
to low levels of cytoplasmic cyclin D3 [68]. These changes 
of CUGBP1 phosphorylation in DM1 myogenesis lead to the 
increase of cyclin D1 in DM1 myoblasts and to the reduction 
p21 in DM1 myotubes [68] (Fig. 7). Cyclin D1 is an impor-
tant regulator of cell proliferation, while p21 a key regulator 
of the transition of dividing myoblasts to differentiation. 
Thus, changes of Akt-CUGBP1-cyclin D1 and cy-
clinD3/cdk4-CUGBP1-p21 pathways in DM1 disease might 
affect the efficiency of myogenesis causing a delay of differ-
entiation. In addition, the phosphorylation of CUGBP1 on 
the putative PKC sites might stabilize CUGBP1 in DM1 
cells leading to the enhancement of CUGBP1 functions. In 
summary, these data show that biological functions of 
CUGBP1 are altered in DM1 patients not only by the eleva-
tion of the protein, but also by phosphorylation-specific 
changes in RNA-binding activity of CUGBP1.  
 
 
 
 
 
 
Fig. (7). The role of signal-transduction pathways in dysregula-
tion of activity of CUGBP1 in patients with DM1. CUGBP1 
structure with three RNA-binding domains (RBD) is shown. Two 
sites (Ser28 and Ser302) phosphorylated by Akt and cyclin D/cdk4 
correspondingly are shown. Amino acid residues predicted to be 
phosphorylated by PKC are also shown. Phosphorylation of 
CUGBP1 at Ser28 increases binding of CUGBP1 to cyclin D1 
mRNA, promoting proliferation in myoblasts. Phosphorylation of 
CUGBP1 by PKC contributes to the stabilization of CUGBP1 in 
DM1. Site-specific phosphorylation of CUGBP1 by cdk4 increases 
interactions of the CUGBP1 with p21 mRNA leading to the eleva-
tion of p21 and promotion of skeletal muscle differentiation. In 
DM1 myogenesis, the reduction of cyclin D3 inhibits CUGBP1 
binding to p21 mRNA and reduces p21 levels leading to a delay of 
DM1 differentiation.  
  Elevation of CUGBP1 in DM2 muscle cells and tissues 
suggests that CUGBP1-dependent pathways might be also 
altered in DM2 cells similar to alterations observed in DM1. 
However, the DM2 phenotype is milder than DM1. Compre-
hensive analysis of CUGBP1 in DM2 cells and in DM2 
models revealed several essential differences in CUGBP1 
function in DM2 compared to DM1. CUGBP1 binds to CUG 
repeats within the DM1 protein extracts mainly as a single 
protein; however, in DM2 extracts, CUGBP1 binds to 
CCUG repeats as a component of the high molecular weight 
CUGBP1-eIF2 complex [52]. As noted above, CUGBP1-
eIF2 complexes are increased in DM2 differentiating myo-
tubes similar to normal myotubes (Fig. 6); suggesting that in 
DM2 myotubes, phosphorylation of CUGBP1 at Ser302 is 
normal. If this is the case, then the RNA-binding activity of 
CUGBP1 toward its RNA targets might be different in DM1 
and in DM2.  
Effects of Elevation of CUGBP1 in DM1 on Stability of 
mRNAs  
  Growing number of evidence indicates that biological 
functions of CUGBP1 are much broader than it has been 
initially suggested. Recent studies demonstrated that 
CUGBP1 is involved in the regulation of stability of short-
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ing to the GRE (GU-rich) elements in their 3’ UTRs [83,84]. 
A large number of CUGBP1 mRNAs targets, stability of 
which may be controlled by CUGBP1, has been identified 
[80,83,87]. Several identified mRNAs control multiple bio-
logical processes in cells. Among those is mRNA encoding 
cytokine TNF (Tumor Necrosis Factor) [80,87]. It has been 
shown that CUGBP1 binds to the 3’ UTR of TNF mRNA 
and destabilizes it through the direct interaction with poly A 
ribonuclease (PARN) removing the poly(A) tail [80]. Con-
sistent with these findings, expression of the mutant DMPK 
in C2C12 myoblasts increases stability of TNF mRNA [87]. 
As the result, TNF is elevated in transfected cells. TNF alpha 
levels are also increased in sera from DM1 patients [88]. 
Increase of TNF alpha in DM1 could be due to inflammation 
associated with dystrophic muscle; but it also could be due to 
increased levels of TNF through the dysregulation of 
CUGBP1. Such dysregulation of RNA stability by CUGBP1 
may contribute to DM1 phenotype at different levels, includ-
ing muscle wasting and insulin resistance.  
  CUGBP1 is homologous to the Xenopus EDEN-BP pro-
tein which regulates RNA deadenylation through EDEN 
element during development [79,81]. Given these additional 
activities of CUGBP1, it is not surprising that lower or high 
levels of expression of CUGBP1 have a toxic effect on nor-
mal development [73,89]. Identification of all CUGBP1 
mRNA targets involved in splicing, translation and RNA 
stability is the next important step to determine the toxicity 
of CUG/CCUG repeats associated with the elevation of 
CUGBP1.  
Toxicity of CUG Repeats Might be Associated with the 
Reduction of Transcription Factors and with Alteration 
of Chromatin Remodeling Proteins 
  In addition to alterations of RNA-binding proteins, the 
mutant CUG repeats affect transcription factors (TFs) by 
leaching Specificity protein 1 (Sp1) and Retinoic Acid Re-
ceptor (RAR) out of active chromatin [40]. These TFs were 
identified in the RNPs containing mutant but not normal 
DMPK mRNA. As the result, these TFs are reduced in DM1 
cells [40]. Like CUGBP1, TFs do not bind to the aggregated 
form of mutant CUG RNA, suggesting that they are affected 
by un-aggregated CUG repeats (Fig. 4). It remains to inves-
tigate if the mutant CCUG repeats affect certain TFs in pa-
tients with DM2. It has been suggested that global transcrip-
tion in DM1 may be affected by mutant CUG repeats indi-
rectly through alterations of splicing [90]. However, other 
mechanisms misregulating transcription in DM1 and DM2 
are possible. In addition to the reduction of TFs due to bind-
ing to soluble CUG repeats, transcription may be changed at 
the levels of chromatin remodeling. Our recent data showed 
that CUGBP1 regulates translation of histone deacethylase 1 
(HDAC1) [91]. This suggests that elevation of CUGBP1 in 
DM1 and DM2 patients might increase HDAC1 levels which 
in turn might alter transcription of many genes. Further stud-
ies are required to test this possibility. 
IDENTIFICATION OF MRNAS REGULATED BY 
CUGBP1 AND MBNL1 IS REQUIRED FOR THE DE-
VELOPMENT OF THERAPY FOR DM 
  Development of approaches reducing toxicity of CUG 
and CCUG repeats requires a better understanding of the 
primary targets of CUG/CCUG repeats. Data discussed 
above suggest that CUG and CCUG repeats affect MBNL1 
and CUGBP1 independently through aggregated and un-
aggregated CUG and CCUG repeats. Early elevation of 
CUGBP1 in transgenic mice expressing CUG repeats shows 
that the increase of CUGBP1 is not a consequence of differ-
ent abnormalities in DM1 but rather a direct result of expres-
sion of the mutant CUG repeats [64]. Evaluation of contribu-
tion of CUGBP1 and MBNL1 in DM1 and DM2 pathologies 
would require identification of mRNAs which are regulated 
by these proteins in vivo. Many attempts have been made to 
determine MBNL1 and CUGBP1 binding sites within 
mRNAs: natural targets of these proteins. So far, the usage 
of numerous methods in vitro has produced contradictory 
observations. It has been initially suggested that MBNL1 
binds exclusively to the double-stranded structures formed 
by long CUG repeats [31]. However, recent reports found 
that MBNL1 binds not to only long repeats, but also to short 
repeats comprising of CUG as well as CAG repeats [92,93]. 
Moreover, MBNL1 is sequestered into nuclear foci formed 
by both CAG and CUG repeats [44]. In addition, the initial 
concept that only long CUG repeats form double-stranded 
RNA structures has been corrected by recent data showing 
that six CUG repeats (CUG6) are sufficient to form double-
stranded helix [94].  
  CUGBP1 has been identified as the protein which binds 
to RNA oligonucleotide containing eight CUG repeats 
(CUG8) [27,28]. CUGBP1 has three RNA-binding domains 
(RBDs). Further studies showed that RBD1+2 interact with 
CUG repeats; while RBD3 of CUGBP1 binds to GCN-rich 
regions in the 5’ UTRs of mRNA targets [ref. 71, and Tim-
chenko L., unpublished]. It has been later shown that 
CUGBP1 also binds to U(A/G) repeat and to GRE elements 
[79,81,83]. As has been discussed above, CUGBP1 does not 
bind to aggregated CUG and CCUG repeats.  
  It seems that the best way to determine biologically rele-
vant binding sites for these proteins is to identify mRNAs 
which are associated with CUGBP1 and MBNL1 in vivo, 
particularly in normal and in DM cells. A comprehensive 
analysis of CUGBP1-RNPs from the CUGBP1 transgenic 
and MBNL1-RNPs from the wild type and MBNL1 knock 
out mice would be one of the approaches for identification of 
mRNAs which are targets of CUGBP1 and MBNL1 in vivo. 
In the case of CUGBP1, it is clearly shown that this protein 
has multiple targets with a variety of binding sites [27,39,69-
76]. Analysis of the targets of CUGBP1 and MBNL1 will 
help to determine the role of each of these proteins in DM1 
and DM2 pathologies.  
PROTEIN TURNOVER IN DM2 
  Although initial studies suggested that DM2 pathology is 
mainly mediated by changing in alternative splicing, further 
studies showed much more complex mechanisms for DM2. 
Examination of cytoplasmic RNA-protein complexes bind-
ing to CCUG repeats revealed that un-aggregated CCUG 
repeats sequester the 20S proteasome [52]. In agreement 
with the sequestration of the 20S proteasome, the stability of 
short-lived proteins is increased in DM2 cells [52]. These 
data suggested that the mutant CCUG repeats outside of the 
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(Fig.  5). In addition, DM2 cells contain abundant transla-
tional CUGBP1-eIF2 complex which changes translation of 
certain proteins in DM2 cells. Interestingly, the 20S protea-
some complex in DM2 cells is associated with ER chaperone 
BiP, which is a master regulator of Unfolded Protein Re-
sponse (UPR). Usually, the UPR signaling prevents protein 
aggregation by two pathways: (1) reduction of translation; 
and by (2) activation of splicing of a specific b-ZIP tran-
scription factor, XBP1, which promotes transcription of 
genes regulating protein degradation. The presence of ER 
chaperones in the CCUG-binding multi-protein complexes 
and the accumulation of undegraded proteins in DM2 cyto-
plasm suggest that ER chaperones play a specific role in the 
attenuation of protein translation, RNA splicing and RNA 
expression in DM2. Thus, ER chaperones may have an addi-
tional toxic effect in DM2 cells.  
  Although majority of data pointed that CCUG expansion 
in the ZNF9 gene has a trans effect on gene expression, data 
in vivo show that ZNF9 deletion causes main symptoms of 
DM2 [95]. Since ZNF9 protein has been implicated in the 
regulation of cap-dependent and cap-independent translation 
through the binding to the 5’ UTRs of mRNAs, it has been 
suggested that ZNF9 might be a candidate to be involved in 
the mis-regulation of protein translation in DM2 [96-98]. 
Consistent with this hypothesis, a recent report has shown 
that ZNF9 interacts with the 5’ UTRs of TOP (terminal oli-
gopyrimidine tract) mRNAs that encode proteins of transla-
tional apparatus: human ribosomal protein, RPS17, poly(A)-
binding protein, PABP, and elongation factors, eEF1A and 
eEF2 [96]. The binding activity of ZNF9 toward the TOP-
containing 5’ UTRs is significantly reduced in DM2 muscle. 
Decrease of proteins of translational apparatus in DM2 cor-
relates with reduction of a rate of global protein synthesis in 
DM2 suggesting that CCUG toxicity is also associated with 
the inhibition of the rate of global protein translation in DM2 
muscle cells.  
COMPARISON OF TOXICITY OF SHORT AND 
LONG CUG AND CCUG REPEATS 
  It has been shown that long CUG repeats in DM1 cells 
are cleaved by a dicer leading to accumulation of RNA con-
taining short CUG repeats [99]. What are the biological con-
sequences of accumulation of short CUG repeats? One pos-
sibility is that short CUG repeats may act as siRNAs regulat-
ing the levels of other genes [99]. Another possibility came 
from several recent observations which suggested that high 
number of copies of normal size of CUG or CCUG repeats 
are as toxic as low number of copies of long CUG and 
CCUG repeats. In DM1 mouse model generated by Dr. Kor-
neluk’s lab, the expression of normal and mutant 3’ UTRs of 
DMPK caused a delay of muscle differentiation and muscle 
atrophy [100]. Elevation of normal 3’ UTR in the DM1 “in-
ducible” transgenic mice caused myotonia, cardiac defects 
and muscular dystrophy [34]. Finally, ectopic expression of 
short CCUG repeats in normal muscle cells increases stabil-
ity of proteins and increases translation of targets of 
CUGBP1 similar to DM2 cells with long expansions [52]. 
These new data suggest that incomplete degradation of ex-
panded DMPK mRNA and mutant intron 1 of ZNF9 may 
produce large number of short CUG and CCUG repeats 
which are toxic products and which may increase the sever-
ity of the disease phenotype. Thus, searching for the thera-
peutic treatments of DM1 and DM2, it would be important to 
develop approaches for the complete elimination of both 
long and short CUG and CCUG repeats. 
CONCLUSIONS 
1.  The toxicity of CUG/CCUG repeats in DM is medi-
ated by following mechanisms: a) reduction of 
MBNL1 in nuclei of DM1 and DM2; b) elevation of 
CUGBP1 in DM1 and DM2; c) alteration of splicing; 
d) increase of CUGBP1 translational targets; e) al-
teration of RNA stability; f) reduction of the rate of 
protein translation; g) reduction of TFs; h) increase of 
protein stability; i) increase of Akt and PKC kinases 
and k) the reduction of cyclin D3.  
2.  The length of CUG/CCUG expansions is critical; 
however, high number of copies of the short CUG 
and CCUG repeats might be also pathogenic. 
3.  Aggregation of CUG and CCUG repeats in nuclei 
might be toxic; however, additional studies are 
needed to examine the correlation of toxicity of the 
total amounts of CUG/CCUG RNA repeats with a 
number of CUG/CCUG nuclear aggregates. 
4.  Disruption of nuclear CUG foci with anti-sense to 
CUG RNA helps to correct MBNL1-dependent splic-
ing in nuclei of DM patients [101,102]. The effect of 
anti-sense on cytoplasmic dysfunctions should be also 
tested.  
5.  Based on the current knowledge, the “ideal” ap-
proaches for DM therapy should include the efficient 
degradation of the mutant RNAs without disruption 
of the wild type DMPK and ZNF9 mRNAs. Such ap-
proaches would help to eliminate complex effects of 
CUG/CCUG repeats on molecular processes in DM 
tissues. 
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